Early Posaconazole Step-Down After 1 Week of Initial Combination Therapy Versus 4-Week Liposomal Amphotericin B Monotherapy for Pulmonary Mucormycosis: An Open-Label Randomized Trial
Early Posaconazole Step-Down After 1 Week of Initial Combination Therapy Versus 4-Week Liposomal Amphotericin B Monotherapy for Pulmonary Mucormycosis: An Open-Label Randomized Trial. // Clinical Microbiology and Infection. – URL: https://www.sciencedirect.com/science/article/pii/S1198743X26006518?dgcid=rss_sd_all
Early Posaconazole Step-Down After 1 Week of Initial Combination Therapy Versus 4-Week Liposomal Amphotericin B Monotherapy for Pulmonary Mucormycosis: An Open-Label Randomized Trial. Clinical Microbiology and Infection. https://www.sciencedirect.com/science/article/pii/S1198743X26006518?dgcid=rss_sd_all
“Early Posaconazole Step-Down After 1 Week of Initial Combination Therapy Versus 4-Week Liposomal Amphotericin B Monotherapy for Pulmonary Mucormycosis: An Open-Label Randomized Trial.” Clinical Microbiology and Infection.
@article{article99939,
title = {Early Posaconazole Step-Down After 1 Week of Initial Combination Therapy Versus 4-Week Liposomal Amphotericin B Monotherapy for Pulmonary Mucormycosis: An Open-Label Randomized Trial},
journal = {Clinical Microbiology and Infection},
url = {https://www.sciencedirect.com/science/article/pii/S1198743X26006518?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...